Unknown

Dataset Information

0

Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement.


ABSTRACT: Sialidosis is an autosomal recessive lysosomal storage disease caused by pathogenic variants in NEU1 which encodes lysosomal sialidase (neuraminidase 1). Lysosomal neuraminidase catalyzes the removal of terminal sialic acid molecules from glycolipids, glycoproteins and oligosaccharides. Sialidosis is classified into two types, based on phenotype and age of onset. Patients with the milder type 1 typically present late, usually in the second or third decade, with myoclonus, ataxia and visual defects. Type 2 is more severe and presents earlier with coarse facial features, developmental delay, hepatosplenomegaly and dysostosis multiplex. Presentation and severity of the disease are related to whether lysosomal sialidase is inactive or there is some residual activity. Diagnosis is suspected based on clinical features and increased urinary bound sialic acid excretion and confirmed by genetic testing showing pathogenic variants in NEU1. We report a patient with type 1 sialidosis who presented mainly with ataxia and both generalized and myoclonic seizures but no visual involvement. Whole exome sequencing of the proband detected compound heterozygous likely pathogenic variants (S182G and G227R) in NEU1.

SUBMITTER: Mohammad AN 

PROVIDER: S-EPMC6047061 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement.

Mohammad Ahmed N AN   Bruno Katelyn A KA   Hines S S   Atwal Paldeep S PS  

Molecular genetics and metabolism reports 20180112


Sialidosis is an autosomal recessive lysosomal storage disease caused by pathogenic variants in <i>NEU1</i> which encodes lysosomal sialidase (neuraminidase 1). Lysosomal neuraminidase catalyzes the removal of terminal sialic acid molecules from glycolipids, glycoproteins and oligosaccharides. Sialidosis is classified into two types, based on phenotype and age of onset. Patients with the milder type 1 typically present late, usually in the second or third decade, with myoclonus, ataxia and visua  ...[more]

Similar Datasets

| S-EPMC8490189 | biostudies-literature
| S-EPMC6751914 | biostudies-literature
| S-EPMC8681143 | biostudies-literature
| S-EPMC7780951 | biostudies-literature
| S-EPMC4552176 | biostudies-literature
| S-EPMC7436437 | biostudies-literature
| S-EPMC8175811 | biostudies-literature
| S-EPMC6175171 | biostudies-literature
| S-EPMC5359383 | biostudies-literature
| S-EPMC8632472 | biostudies-literature